HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: AJPH.2005.078105v1 97/1/110    most recent Submit a response View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Heimer, R. Articles by Singer, M. Search for Related Content PubMed PubMed Citation Articles by Heimer, R. Articles by Singer, M. Related Collections Health Policy HIV/AIDS Prevention Public Health Practice Surveillance Urban Health

Robert Heimer, PhD, Lauretta E. Grau, PhD, Erin Curtin, MPH, Kaveh Khoshnood, PhD and Merrill Singer, PhD

Robert Heimer is with the Departments of Epidemiology and Public Health and Pharmacology, Yale University School of Medicine, New Haven, Conn. Lauretta E. Grau and Kaveh Khoshnood are with the Department of Epidemiology and Public Health, Yale University School of Medicine. At the time the study was conducted, Erin Curtin was with the Yale University School of Public Health. Merrill Singer is with the Hispanic Health Council, Hartford, Conn.

Correspondence: Requests for reprints should be sent to Robert Heimer, Department of Epidemiology and Public Health, Yale University School of Medicine, PO Box 208034, 60 College St, New Haven, CT 06520–8034 (e-mail: robert.heimer{at}yale.edu).

Objectives. We sought to determine the extent of HIV testing among urban injection drug users (IDUs) to assess whether an expansion of targeted testing programs would be consistent with national goals to identify previously undetected infections.

Methods. IDUs in 5 US cities (Oakland, Calif; Chicago, Ill; Hartford and New Haven, Conn; and Springfield, Mass) were recruited either by chain referral or time–location sampling. The IDUs were questioned about HIV testing, and factors associated with HIV testing were analyzed.

Results. Ninety-three percent of 1543 IDUs had been tested. Among those tested but who did not report having been told that they were HIV seropositive, 90% had been tested within the past 3 years. Women and syringe-exchange customers were more likely to have been tested ever and in the recent past. We estimated the number of undetected infections among urban IDUs in the United States to be less than 40000.

Conclusions. Testing for HIV has reached the vast majority of IDUs through the current options. Expending scarce prevention money to expand testing of IDUs is unlikely to be productive. Instead, resources should be used for proven HIV-prevention strategies including syringe exchange, drug treatment, and secondary prevention for those who are HIV positive

This article has been cited by other articles:

				M. W. Ross, S. A. McCurdy, G. P. Kilonzo, M. L. Williams, and M. T. Leshabari Drug Use Careers and Blood-borne Pathogen Risk Behavior in Male and Female Tanzanian Heroin Injectors Am J Trop Med Hyg, September 1, 2008; 79(3): 338 - 343. [Abstract] [Full Text] [PDF]

				C. G. Beckwith, N. Zaller, and T. P. Flanigan HIV COUNSELING AND TESTING AMONG INJECTION DRUG USERS NEEDS TO CONTINUE Am J Public Health, July 1, 2007; 97(7): 1161 - 1161. [Full Text] [PDF]